AGC Inc.

Until this gets started, welcome to the earnings briefing of AGC Inc. for the third quarter of this call year, 2026. My name is Kazumi Tamaki, General Manager for Corporate Communications and Investor Relations, serving as moderator. Today's attendees are Yoshio Takegawa, Executive Vice President and CFO, Shikko Yaku-in, and Tomoyuki Shiokawa, Executive Officer, General Manager of Finance and Control Division. First, CFO Takegawa will provide an overview of the financial results for the third quarter. We will then have a question-and-answer session. We are planning to finish at 3.50 p.m. Your cooperation is appreciated. I now ask CFO Takegawa to start the presentation. I am Takegawa, CFO. Thank you for joining us. Please turn to page 3. Key points of cumulative results for the third quarter of 2026 and the four-year forecast. Year-on-year, net sales increased by 105.5 billion yen, while operating profit decreased by 1.9 billion. Shipments increased for chemicals in general and electronic materials, and prices increased for integrated chemicals and architectural glass in Europe. Steel profit decreased due to deteriorating profits for essential chemicals Southeast Asia, automotive in Europe and the Americas, and architectural glass in Europe, on higher material prices and manufacturing costs. Also, profitability improvement measures were recorded in other income and expenses. Full year forecast is revised downward due to higher costs in automotive and essential chemicals Southeast Asia and lower than expected volumes in architectural, glass, and life science. Also, other expenses are projected to be higher than last year and the initial forecast.

Please turn to page 6.

A closer look at third quarter results using the income statement year-on-year comparison. Sales were 1,662.6 billion, up 150.5 billion, despite such negatives as lower shipments of architectural glass and life science, owing to such positives as weaker yen Thank you very much. Business profit was 76.2 billion, down 1.1 billion, despite such positives as gain on sale of affiliates and the absence of impairment losses on biopharmaceuticals CDMOs recorded in the previous year, due to higher costs for restructuring programs and loss and sale of property, plant, and equipment. Profit before tax was $70.4 billion, down $2.8 billion, and profit attributable to owners of the parent was $33.4 billion, down $6.1 billion. Page 7 Results by segment Architectural glass, automotive, and electronics posted increased sales and decreased profit, while chemicals saw increased sales and profit. Life Science posted improved profitability, page 8. Year-on-year and quarter-on-quarter variance analysis of operating profit. First, year-on-year decline at 1.9 billion. Sales volume, price, and product mix, positive 32.3 billion due to increased shipments of chemicals in general and electronic materials. as well as pricing policies in integrated chemicals and architectural glass Europe. Fuels and raw materials, negative 17.7 billion, with chemicals and architectural glass Europe particularly affected. Cost in others, negative 16.6 billion, due to increased depreciation and cost increases in automotive in Europe and the Americas. Quarter-and-quarter, increase of 2 billion. Page 9 During the first nine months, we implemented various profitability improvement measures as reflected in other income and expenses. Main items were as follows. In architectural class, workforce optimization and other structural improvements in response to sluggish demand in Europe. In automotive, sales of replacement glass installation business in Europe to concentrate resources on upstream businesses. In chemicals, decision to end production at the Integrated Chemicals UK site by year-end, following weak performance due to rising costs. In life science, sale of Colorado CDMO site completed, except for part of the land. Accordingly, ¥15.5 billion in other income and ¥32.2 billion in other expenses were recorded up to June 3.